Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 12776 - 12800 of 15432 in total
FB-101 is a c-Abl inhibitor. Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).
Experimental
Investigational
Matched Description: … , it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and
SRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity...
Investigational
Matched Description: … in treating eczema, itching and inflammation. ... Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and
Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Vet approved
Withdrawn
CCX354-C has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
Experimental
Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Experimental
Matched Description: … inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and
G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabolically active.
Investigational
Matched Description: … It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabolically …
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration...
Investigational
Matched Description: … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and
NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
Investigational
VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated...
Investigational
Investigational
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
Investigational
Matched Description: … BZL101 targets diseased cells while leaving normal cells healthy and intact. …
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Investigational
Matched Description: … It is under investigation by Pfizer and has gone through phase I of the clinical trails. …
Bemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Experimental
Matched Description: … It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose. …
Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease).
Investigational
Matched Description: … Lorecivivint is under investigation in clinical trial NCT03246399 (A Study of the Safety, Tolerability, and
MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies).
Investigational
Matched Description: … 6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and
MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK-0773 in Women With Sarcopenia (Loss of Muscle Mass)(mk-0773-005)).
Investigational
Matched Iupac: … (4aS,4bS,6aS,7S,9aS,9bS,11aR)-3-fluoro-N-({1H-imidazo[4,5-b]pyridin-2-yl}methyl)-1,4a,6a-trimethyl-2- …
Matched Description: … MK-0773 is under investigation in clinical trial NCT00529659 (A Study of the Safety and Efficacy of MK …
Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)).
Investigational
Matched Description: … clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and
AUTO3 is bicistronic chimeric antigen receptor T-cell therapy investigated for acute lymphoblastic leukemia (ALL). It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22.
Investigational
Matched Description: … It is an investigational chimeric antigen receptor (CAR) T cell treatment targeting CD19 and CD22. …
Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
Investigational
Matched Description: … It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and
CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.
Investigational
Matched Description: … CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. …
Displaying drugs 12776 - 12800 of 15432 in total